Cargando…

Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia

INTRODUCTION: Ethiopia has one of the highest HIV burdens in sub-Saharan Africa. Despite the fact that second-line antiretroviral therapy (ART) has been available for more than ten years, studies on its effectiveness are scarce. OBJECTIVE: To assess treatment outcomes and predictors of unfavorable o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gidey, Kidu, Mache, Abadi, Hailu, Berhane Yohannes, Asgedom, Solomon Weldegebreal, Tassew, Segen Gebremeskel, Nirayo, Yirga Legesse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390760/
https://www.ncbi.nlm.nih.gov/pubmed/37534062
http://dx.doi.org/10.2147/IDR.S419348
_version_ 1785082547996196864
author Gidey, Kidu
Mache, Abadi
Hailu, Berhane Yohannes
Asgedom, Solomon Weldegebreal
Tassew, Segen Gebremeskel
Nirayo, Yirga Legesse
author_facet Gidey, Kidu
Mache, Abadi
Hailu, Berhane Yohannes
Asgedom, Solomon Weldegebreal
Tassew, Segen Gebremeskel
Nirayo, Yirga Legesse
author_sort Gidey, Kidu
collection PubMed
description INTRODUCTION: Ethiopia has one of the highest HIV burdens in sub-Saharan Africa. Despite the fact that second-line antiretroviral therapy (ART) has been available for more than ten years, studies on its effectiveness are scarce. OBJECTIVE: To assess treatment outcomes and predictors of unfavorable outcomes in HIV patients receiving second-line ART at Ayder Comprehensive Specialized Hospital and Mekelle Hospital. MATERIALS AND METHODS: An institution-based retrospective cohort study was conducted in two hospitals in Tigray Region, Ethiopia. We evaluated 192 patients aged ≥15 years who were switched to second-line from November 2009 to May 2020 after failure of first-line ART. The primary outcome was the time from the initiation of second-line ART to the occurrence of unfavorable treatment outcomes (treatment failure, death, and loss to follow-up). We performed Kaplan–Meier survival estimates to calculate the cumulative incidence rates of unfavorable outcomes. RESULTS: The mean age (SD) at the initiation of second-line ART was 39 (10.03) years, and the median CD4 cell count was 121 cells/microL. During a median follow-up of 4.6 years, 24 (12.5%) patients had died, 11 (5.7%) patients were lost to follow up, and 47 (24,4%) patients were experienced treatment failure. The incidence rates for unfavorable outcomes were 7.8 per 100 patients/years. Predictors for unfavorable outcomes were body mass index (BMI) <18.5 (adjusted hazard ratio [aHR] = 2.51, 95% confidence interval (CI): 1.27–4.95) and CD4 counts ≤100 cells/microL (aHR = 1.74, 95% CI: 1.09–2.79). Despite the failure of second-line ART, none of the patients received third-line ART. CONCLUSION: The incidence rate of unfavorable treatment outcomes for second-line ART was found to be high. A low BMI and a low baseline CD4 count were significant predictors of unfavourable outcomes and should be given special consideration in HIV care. A third-line ART regimen should also be considered for people who have failed second-line ART.
format Online
Article
Text
id pubmed-10390760
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103907602023-08-02 Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia Gidey, Kidu Mache, Abadi Hailu, Berhane Yohannes Asgedom, Solomon Weldegebreal Tassew, Segen Gebremeskel Nirayo, Yirga Legesse Infect Drug Resist Original Research INTRODUCTION: Ethiopia has one of the highest HIV burdens in sub-Saharan Africa. Despite the fact that second-line antiretroviral therapy (ART) has been available for more than ten years, studies on its effectiveness are scarce. OBJECTIVE: To assess treatment outcomes and predictors of unfavorable outcomes in HIV patients receiving second-line ART at Ayder Comprehensive Specialized Hospital and Mekelle Hospital. MATERIALS AND METHODS: An institution-based retrospective cohort study was conducted in two hospitals in Tigray Region, Ethiopia. We evaluated 192 patients aged ≥15 years who were switched to second-line from November 2009 to May 2020 after failure of first-line ART. The primary outcome was the time from the initiation of second-line ART to the occurrence of unfavorable treatment outcomes (treatment failure, death, and loss to follow-up). We performed Kaplan–Meier survival estimates to calculate the cumulative incidence rates of unfavorable outcomes. RESULTS: The mean age (SD) at the initiation of second-line ART was 39 (10.03) years, and the median CD4 cell count was 121 cells/microL. During a median follow-up of 4.6 years, 24 (12.5%) patients had died, 11 (5.7%) patients were lost to follow up, and 47 (24,4%) patients were experienced treatment failure. The incidence rates for unfavorable outcomes were 7.8 per 100 patients/years. Predictors for unfavorable outcomes were body mass index (BMI) <18.5 (adjusted hazard ratio [aHR] = 2.51, 95% confidence interval (CI): 1.27–4.95) and CD4 counts ≤100 cells/microL (aHR = 1.74, 95% CI: 1.09–2.79). Despite the failure of second-line ART, none of the patients received third-line ART. CONCLUSION: The incidence rate of unfavorable treatment outcomes for second-line ART was found to be high. A low BMI and a low baseline CD4 count were significant predictors of unfavourable outcomes and should be given special consideration in HIV care. A third-line ART regimen should also be considered for people who have failed second-line ART. Dove 2023-07-27 /pmc/articles/PMC10390760/ /pubmed/37534062 http://dx.doi.org/10.2147/IDR.S419348 Text en © 2023 Gidey et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gidey, Kidu
Mache, Abadi
Hailu, Berhane Yohannes
Asgedom, Solomon Weldegebreal
Tassew, Segen Gebremeskel
Nirayo, Yirga Legesse
Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title_full Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title_fullStr Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title_full_unstemmed Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title_short Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia
title_sort second-line antiretroviral treatment outcomes and predictors in tigray region, ethiopia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390760/
https://www.ncbi.nlm.nih.gov/pubmed/37534062
http://dx.doi.org/10.2147/IDR.S419348
work_keys_str_mv AT gideykidu secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia
AT macheabadi secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia
AT hailuberhaneyohannes secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia
AT asgedomsolomonweldegebreal secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia
AT tassewsegengebremeskel secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia
AT nirayoyirgalegesse secondlineantiretroviraltreatmentoutcomesandpredictorsintigrayregionethiopia